35 Stocks Moving In Tuesday's Mid-Day Session

Gainers

• Cumberland Pharmaceuticals Inc. CPIX shares jumped 105.9% to $4.53. The FDA approved expanded labeling for Cumberland Pharmaceuticals’ Caldolor, an intravenously delivered formulation of ibuprofen, to now include use in pre-operative administration.
• Adagio Therapeutics, Inc. ADGI gained 52.7% to $71.51. Adagio Therapeutics gained more than 86% on Monday after the company said its COVID-19 monoclonal antibody, ADG20, is likely to retain activity against Omicron, as observed in in vitro models with all other variants of concern identified previously.
• Pioneer Power Solutions, Inc. PPSI shares climbed 33.8% to $10.21 after dipping 27% on Monday.
• ImmunoGen, Inc. IMGN gained 30.1% to $6.18 in reaction to positive topline data from the SORAYA trial of mirvetuximab soravtansine for ovarian cancer. The trial is evaluating mirvetuximab as monotherapy in patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer who have been previously treated with Roche Holdings AG's RHHBY Avastin (bevacizumab).
• Vir Biotechnology, Inc. VIR jumped 20.8% to $48.90 after HC Wainwright & Co maintained a Buy rating on the stock and raised its price target from $135 to $200.
• Context Therapeutics Inc. CNTX shares rose 20% to $6.70 after climbing 9% on Monday.
• Molecular Partners AG MOLN rose 16.6% to $13.86 after the company confirmed retained activity of ensovibep on the positions mutated in emerging omicron variant of SARS-CoV-2 in vitro.
• ContraFect Corporation CFRX surged 16.4% to $3.75.
• MEI Pharma, Inc. MEIP gained 16.2% to $2.8483. MEI Pharma and Kyowa Kirin Co announced data from the pivotal Phase 2 TIDAL studyof zandelisib as a single agent for follicular lymphoma (FL) patients who received at least two prior systemic therapies.
• ERYTECH Pharma S.A. ERYP rose 15.4% to $2.75 after the company secured US patent directed to sequential use of methioninase & asparaginase against solid tumors.
• Seres Therapeutics, Inc. MCRB surged 14% to $10.07. Seres Therapeutics said first patient was enrolled in Phase 1b study of SER-155 investigational microbiome therapeutic to reduce the risk of antibiotic-resistant bacterial infections and graft-versus-host disease.
• Bakkt Holdings, Inc. BKKT gained 13% to $17.32.
• Clarus Therapeutics Holdings, Inc. CRXT jumped 12.8% to $5.88 after the company announced issuance of two new patents for JATENZO.
• Genetron Holdings Limited GTH surged 10.7% to $10.63 following Q3 results. Genetron Health announced Late monday, a co-development agreement with AstraZeneca R&D China for personalized MRD tests for solid tumors in China.
• Chimerix, Inc. CMRX gained 8% to $6.33.
• BeyondSpring Inc. BYSI rose 7.6% to $14.00 after tumbling over 9% on Monday.
• Adagene Inc. ADAG rose 7.2% to $9.11 after the company reported the FDA clearance of IND for Phase 1b/2 trial of anti-CTLA-4 monoclonal antibody ADG116 in combination therapy with anti-PD-1 antibody pembrolizumab.

Check out these big penny stock gainers and losers

Losers

• AeroClean Technologies, Inc. AERC fell 56.2% to $51.39 after jumping around 45% on Monday.
• Olema Pharmaceuticals, Inc. OLMA shares dipped 56% to $9.64 after the company announced first clinical data from the Phase 1 dose-escalation portion of the ongoing Phase 1/2 clinical trial of OP-1250.
• TG Therapeutics, Inc. TGTX fell 39.9% to $14.05 after the company reported the FDA plans to host a meeting of the Oncologic Drugs Advisory Committee in connection with its review of the pending BLA/sNDA for the combination of ublituximab and UKONIQ.
• Palatin Technologies, Inc. PTN shares fell 21.6% to $0.6706 after gaining more than 50% on Monday.
• Petros Pharmaceuticals, Inc. PTPI dipped 20% to $3.2001 after surging over 91% on Monday.
• Barnes & Noble Education, Inc. BNED fell 19.7% to $7.14 after the company reported worse-than-expected Q2 EPS and sales results.
• cbdMD, Inc. YCBD fell 18.8% to $1.5750. CbdMD shares jumped 30% on Monday after the company announced a multi-year exclusive agreement with Amify, an Amazon.com platform partner.
• StoneX Group Inc. SNEX dropped 18.4% to $53.63 following Q4 results.
• Biofrontera Inc. BFRI fell 15% to $6.03 following Q3 results.
• NRx Pharmaceuticals, Inc. NRXP fell 14.6% to $6.92. NRx Pharmaceuticals rose 20% on Monday after the company announced positive data from its ZYESAMI study.
• Baozun Inc. BZUN dipped 13.3% to $12.86 as the company reported third-quarter FY21 revenue growth of 3.8% year-on-year to $294.7 million (RMB1.9 billion), missing the consensus of $303.5 million.
• RLX Technology Inc. RLX fell 13% to $4.41.
• Longeveron Inc. LGVN dipped 11.8% to $23.15 after dropping 14% on Monday.
• Pasithea Therapeutics Corp. KTTA fell 10.3% to $3.81.
• Dillard's, Inc. DDS dipped 10% to $305.94.
• Array Technologies, Inc. ARRY fell 9.8% to $20.61 after the company reported a proposed private offering of $325 million of convertible senior notes.
• Micro Focus International plc MFGP fell 7.9% to $4.6042. Micro Focus, earlier during the month, announced it will sell its archiving and risk management portfolio to Smarsh.
• Valneva SE VALN fell 6.2% to $63.13. Valneva shares climbed around 13% on Monday after the company and IDT Biologika announced a collaboration to produce Valneva's inactivated COVID-19 vaccine candidate VLA2001.